Market Size of Expectorant Drugs Industry
Study Period | 2019-2029 |
Market Size (2024) | USD 100 Million |
Market Size (2029) | USD 120 Million |
CAGR (2024 - 2029) | 4.50 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Expectorant Drugs Market Analysis
The Expectorant Drugs Market size is estimated at USD 100 million in 2024, and is expected to reach USD 120 million by 2029, growing at a CAGR of 4.5% during the forecast period (2024-2029).
The COVID-19 pandemic had a significant impact on the expectorant drugs market. The initial virus outbreak led to a surge in the demand for over-the-counter (OTC) expectorants as people sought relief from respiratory symptoms associated with COVID-19. The rise in respiratory illnesses like influenza has led to a higher demand for expectorants, which help clear mucus from the airways. This can strain supply chains and lead to shortages of expectorant drugs globally. Post-COVID-19 complications like lung fibrosis and chronic obstructive pulmonary disease (COPD) were growing concerns. Expectorants can play a role in managing such conditions, potentially boosting market growth. For instance, COPD takes over 3 million lives each year, impacting an estimated 392 million people globally. Out of these, three-quarters of individuals live in low-middle countries with COPD conditions. People with COPD Condition further require expectorant drugs to treat the disease, which is expected to increase the demand for the expectorant market further.
Furthermore, the growing incidence of respiratory infections, rising seasonal fluctuations, and easier medication access are expected to expand the market. Respiratory illnesses like the common cold, influenza, and chronic obstructive pulmonary disease (COPD) are rising globally. For instance, in October 2022, according to the Centers for Disease Control and Prevention (CDC), during the 2021-2022 season, influenza caused a significant burden on healthcare systems, with an estimated 9.4 million people suffering from the illness, 4.3 million required medical visits and 1,00,000 seeking hospitalizations. Additionally, in October 2023, data published by the World Health Organization (WHO) showed that about 1 billion people experience seasonal influenza yearly, with 3 to 5 million cases progressing to severe illness. Thus, expectorant drugs are used heavily in respiratory conditions, raising the demand for expectorant drugs.
Moreover, the senior population is more susceptible to respiratory illnesses like bronchitis, pneumonia, and asthma due to a weakened immune system, slower lung function, and underlying health conditions. For instance, in November 2023, according to UNICEF (United Nations Children's Fund), pneumonia is a prevalent infectious disease among children, with 1,400 cases of pneumonia per 100,000 children worldwide. Due to rising cases of pneumonia among adults and children, there will be a further need for expectorant drugs to treat the patient, which will increase the market expansion in the forecast period.
Due to the factors above, such as rising cases of respiratory infections, adoption of telemedicine, awareness among people about respiratory conditions, and increasing geriatric population, the market is expected to continue to grow in the coming years.
However, governments and regulatory bodies impose strict guidelines regarding the sale and use of expectorant drugs. Certain countries have banned or restricted codeine-containing cough suppressants due to safety concerns.
Expectorant Drugs Industry Segmentation
As per the scope of the report, expectorant drugs are medications that help loosen and clear mucus from the respiratory tract. They work by stimulating the production of fluids in the airways, which helps to thin the mucus and make it easier to cough up. Expectorants are often used to treat coughs and congestion associated with colds, flu, and other respiratory infections.
The expectorant drugs market is segmented by product, dosage form, distribution channel, and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). By product, the market is segmented into over-the-counter (OTC) and prescription drugs. By dosage form, the market is segmented into inhalant, oral solid, and oral liquid. By distribution channel, the market is segmented into hospital pharmacies, retail stores, drug stores, and online pharmacies. The report also covers the market size and forecasts for the wooden decking market in 11 countries across major regions.
For each segment, the market sizing and forecasts have been done based on revenue (USD).
By Product | |
Over-the-Counter (OTC) | |
Prescription Drug |
By Dosage Form | |
Inhalant | |
Oral Solid | |
Oral Liquid |
Distribution Channel | |
Hospital Pharmacies | |
Retail Stores | |
Drug Store | |
Online Pharmacies |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Expectorant Drugs Market Size Summary
The expectorant drugs market is poised for steady growth over the forecast period, driven by an increasing prevalence of respiratory illnesses and the rising demand for over-the-counter (OTC) medications. The market's expansion is significantly influenced by the aftermath of the COVID-19 pandemic, which heightened the demand for expectorants to alleviate respiratory symptoms. The growing incidence of conditions such as chronic obstructive pulmonary disease (COPD) and seasonal influenza further propels the need for these drugs. The senior population, more susceptible to respiratory ailments, and the rising cases of pneumonia among children and adults also contribute to market growth. The accessibility and affordability of OTC expectorants, coupled with their effectiveness in treating common respiratory conditions, make them a preferred choice for consumers, thereby enhancing market dynamics.
North America is expected to dominate the expectorant drugs market due to the high prevalence of respiratory diseases and a rapidly aging population. The region's market growth is supported by significant research and development activities and the presence of key pharmaceutical players. The introduction of new products and regulatory approvals, such as those by Merck KGaA and Marksans Pharma, further bolster market expansion. The competitive landscape is moderately fragmented, with several global and regional companies vying for market share. Major players focus on obtaining regulatory approvals and launching new products to strengthen their market presence. As the demand for expectorant drugs continues to rise, driven by both health concerns and consumer preferences, the market is expected to witness substantial growth in the coming years.
Expectorant Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Respiratory Disease
-
1.2.2 Growing Demand for OTC Medications
-
-
1.3 Market Restraints
-
1.3.1 Governments and Regulatory Bodies Impose Strict Guidelines
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value)
-
2.1 By Product
-
2.1.1 Over-the-Counter (OTC)
-
2.1.2 Prescription Drug
-
-
2.2 By Dosage Form
-
2.2.1 Inhalant
-
2.2.2 Oral Solid
-
2.2.3 Oral Liquid
-
-
2.3 Distribution Channel
-
2.3.1 Hospital Pharmacies
-
2.3.2 Retail Stores
-
2.3.3 Drug Store
-
2.3.4 Online Pharmacies
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Expectorant Drugs Market Size FAQs
How big is the Expectorant Drugs Market?
The Expectorant Drugs Market size is expected to reach USD 100 million in 2024 and grow at a CAGR of 4.5% to reach USD 120 million by 2029.
What is the current Expectorant Drugs Market size?
In 2024, the Expectorant Drugs Market size is expected to reach USD 100 million.